KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2025)

Amneal Pharmaceuticals has reported Income from Continuing Operations over the past 9 years, most recently at 49573000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 49573000.0 for Q4 2025, up 339.0% from a year ago — trailing twelve months through Dec 2025 was 127933000.0 (up 273.17% YoY), and the annual figure for FY2025 was 127933000.0, up 273.17%.
  • Income from Continuing Operations for Q4 2025 was 49573000.0 at Amneal Pharmaceuticals, up from 18132000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AMRX hit a ceiling of 49573000.0 in Q4 2025 and a floor of 240081000.0 in Q2 2022.
  • Median Income from Continuing Operations over the past 5 years was 4683500.0 (2022), compared with a mean of 11465300.0.
  • Peak annual rise in Income from Continuing Operations hit 1148.41% in 2023, while the deepest fall reached 1483.18% in 2023.
  • Amneal Pharmaceuticals' Income from Continuing Operations stood at 20419000.0 in 2021, then surged by 71.12% to 5896000.0 in 2022, then plummeted by 1483.18% to 93344000.0 in 2023, then surged by 77.78% to 20742000.0 in 2024, then skyrocketed by 339.0% to 49573000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 49573000.0 (Q4 2025), 18132000.0 (Q3 2025), and 35610000.0 (Q2 2025) per Business Quant data.